Entera Bio reports strong financial results and progress in developing oral peptide drugs

From GlobeNewswire: 2024-08-09 16:05:00

Entera Bio Ltd. reported strong financial results and key updates for Q2 2024. The company is focused on developing orally delivered peptides for various diseases. EB613, an oral osteoporosis drug, is advancing towards an FDA ruling. EB612 for hypoparathyroidism and GLP-2/GLP-1 tablet for obesity are also in development.

EB613, the first oral PTH(1-34) daily osteoanabolic tablet for osteoporosis, showed positive results in a phase 2 study and is projected to enter phase 3 by 2025. EB612, a peptide replacement therapy for hypoparathyroidism, is progressing to phase 2 development. Entera is also working on GLP-2 and GLP-1/Glucagon agonist tablets.

Financially, as of June 30, 2024, Entera had $9.1 million in cash. Research and development expenses decreased slightly, and net loss for Q2 2024 was $2.1 million. The company expects its cash reserves to meet operating needs until Q3 2025. Entera’s pipeline includes five oral peptide programs aiming to transform healthcare standards.



Read more at GlobeNewswire:: Entera Bio Reports Q2 2024 Financial Results and Provides